The scenario of chronic kidney disease (CKD) management has been transformed by the advent of sodium glucose co-transporter-2 ...

Results to be Presented at the European Society for Cardiology Congress Demonstrate Differential Effects During Endothelial Dysfunction in Cell Studies A manuscript entitled “Metabolic, Intestinal, ...

A new Northwestern Medicine study has shed light on how a class of diabetes drugs may protect the kidneys—not just by ...

When canagliflozin (Invokana) was approved in 2013, the SGLT2 inhibitor was touted as a first in a new medication class that was, at the time, the only oral, once-daily medication to reduce blood ...

Empagliflozin stabilizes kidney function and reduces heart failure risk post-myocardial infarction, with eGFR remaining stable over 24 months. The EMPACT-MI trial confirmed empagliflozin's safety when ...

SGLT2 inhibitors were more cardioprotective in older people, but reduced HbA1c less with age. GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. Sex ...

Please provide your email address to receive an email when new articles are posted on . Concurrent use of finerenone and empagliflozin reduced urine albumin-to-creatinine ratio for adults with CKD and ...

SGLT2 inhibitor use might be renoprotective in patients with ADPKD, but could increase kidney volume. Dapagliflozin might help protect kidney function in patients with autosomal dominant polycystic ...

In patients with T2D, the risks for gastroesophageal reflux disease and related complications are greater with GLP-1 RA ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Receipt of an SGLT-2 inhibitor for type 2 diabetes in ...